Zytiga TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: abiraterone
Brand name
(ARTG)
: ZYTIGA abiraterone acetate 500 mg film-coated tablet blister packDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
ZYTIGA is indicated in combination with prednisone or prednisolone for the treatment of: newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT), or patients with metastatic advanced prostate cancer (castration resistant prostate cancer, mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT) or patients with mCRPC who have received prior chemotherapy containing a taxane.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Tablet, film coated
- Oral
- Purple oval shaped film-coated tablet debossed with AA on one side and 500 on the other side.
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 3 Years.
Do I need a prescription ?
(ARTG)
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient abiraterone
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems